|
Post by kc on May 30, 2017 12:50:04 GMT -5
So they need to bring in a seasoned CFO (I would say best of luck with current financial position) as well as a replacement CCO for Mike since he is now steering the ship for the entire company not just Afrezza. I'm not looking too much into press release but it did seem a little Afrezza heavy without mentioning any techno pipeline products. Who knows anymore. I couldn't resist.....
Maybe Amgen has a seasoned CFO?
|
|
|
Post by kc on May 30, 2017 10:04:16 GMT -5
After the Hakan mess and SNY bailing out I thought who would want to take on the job of CEO of a ship that had just sunk? Desisto bailed because it was obvious this was a no-win situation unless a rabbit could be pulled out of a hat. There were no rabbits in the hat. Matt took on the job. Was he in over his head? Yes, but I give him a lot of credit for what he did accomplish and kept us on life support. I think he deserves our gratitude and not bashing. Desisto did not bail. He had an enforceable Not to Compete agreement.
|
|
|
Post by kc on May 30, 2017 10:01:56 GMT -5
This has been in the works. Matt was not fired. Those two are not mutually exclusive. I agree that it had probably been in the works for a while going back to the DeSisto failure. Matt wanted the CEO role and there was no obvious replacement for DeSisto so the BOD let him have it, after all he was a known quantity. Matt has failed in the CEO role though and the BOD had to replace him which they have. Matt is a good technician, but a poor strategist so as a wartime CEO he will not succeed. As I said in a post a while back we need a wartime CEO and I think that is what we get with Mike. I think this is very positive move. He is inexperienced, but that is not necessarily a bad thing since his role is to lead the fight back rather than get into the operational side of the company (Rose is more than capable of dealing with that). I disagree with you that Matt failed in the CEO role. He did a great job and brought us from the depth's of the great abyss. He started with nothing on the day after the Sanofi notice in Jan 2016. Great Job Matt. We owe him respect for what he accomplished and helping to put MannKind in a better place. It didn't happen as easy or fast as shareholders would have liked but he did help building a team. Nothing came easy.
|
|
|
Post by kc on May 30, 2017 9:21:45 GMT -5
This has been in the works. Matt was not fired. IMO you are right. That's why I said before the shareholder meeting that there would be changes. And my question was how much to the BOD and management disagree on how to move forward. Now this explains why no Q & A at the shareholders meeting. Seemed like a lot of song and dance but not Q & A. I am still waiting for the 13D or G to be filed. Will it be buy into MannKind? Who knows. But something is in the works.
|
|
|
Post by kc on May 30, 2017 8:27:10 GMT -5
I dont view this as a catalyst. Say what you will about Matt, the company needs to deal with its Deerfield debt and complete a money raise somewhere.
If partnership deals with upfront money arent near completion the company doesnt have someone with a skillset to deal with these challenges. I guess we will learn that shortly on the Deerfield Debt. There must be something big brewing for MannKind.
|
|
|
Post by kc on May 30, 2017 8:22:21 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1028218VALENCIA, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) announced today that its Board of Directors appointed Michael Castagna, Pharm.D., as Chief Executive Officer effective May 25, 2017. Dr. Castagna replaced Matthew Pfeffer, who served as both CEO and Chief Financial Officer since January 2016 and as CFO from 2008 to 2016. To facilitate an orderly transition, Mr. Pfeffer will continue with the company in an advisory capacity until the end of July 2017. In addition, on May 25, 2017, Dr. Castagna was appointed to the board of directors of MannKind. Kent Kresa, Chairman of the Board, said, "The Board is extremely grateful to Matt for his committed service to the company over the past nine years. Matt successfully set the foundation for the company during its transition into a commercial entity and effectively prepared Michael to be his successor." Mr. Kresa continued, "Michael demonstrated deep commercial expertise in his prior role as MannKind's Chief Commercial Officer as he built the capabilities from the bottom-up necessary to position Afrezza and the company for future growth. Under Michael's leadership, new prescriptions of Afrezza have shown a steady increase since the MannKind launch and future prospects for this innovative product are strong. The Board is excited to move forward under Michael's leadership." Dr. Castagna said, "I am honored to lead MannKind into its next phase of growth. Our inhaled insulin, Afrezza, is a truly differentiated brand that will help millions of people suffering from diabetes. Our relentless focus on empowering people to conquer the daily struggle of managing their diabetes will set MannKind apart." Rose Alinaya, currently the company's Senior Vice President and Principal Accounting Officer, will take over the role of Acting Chief Financial Officer until a permanent CFO is named. Dr. Castagna said, "I am happy to have Rose in this position as I will benefit greatly from her 14 years of experience with MannKind. She will be a key asset for me as I take on my new role." hmmm, this is a surprise. The biggest surprise is, "Mr. Pfeffer will continue with the company in an advisory capacity until the end of July 2017." Need to get his Stock options for his service. Perhaps some news ahead.
|
|
|
Post by kc on May 28, 2017 17:54:31 GMT -5
A co-worker's T1 son is preparing to visit my doctor and ask for Afrezza. Will insurance automatically reject his request? Any suggestions? What is the age of the son? Over 18?
|
|
|
Post by kc on May 28, 2017 9:32:36 GMT -5
Just think if instead of VDEX MannKind made a deal with Walgreens healthcare clinic's or CVS Minute Clinics and targeted both T1D and TD2 patients Tied into the One Drop Technology. Think about how many opportunities the company would have to sell the product. While VDEX has not been the success any of us said hope for perhaps MannKind should try to do a test market with either Walgreens or CVS. Drug manufacturers are not allowed to "make deals" with doctors to prescribe their medications... at least not if the doctors accept any kind of government funded health payments (Medicare, Medicaid, etc.), which I'm sure all of those clinics do. VDEX did not have any connection financially with MNKD... there was no deal, it was simply founded by people that believed in Afrezza, and very well might have had an investment in MNKD, but that apparently isn't against the rules despite seemingly causing the same sort of financial conflict of interest. My words dictated didn't come across correctly. I know that MannKind did not make a deal with VDEX. It would also be up to the managers of a Minute clinic or Walgreens Healthclinic to set up their own diabetes clinic. But it does seem like it would be a winner.
|
|
|
Post by kc on May 27, 2017 22:28:56 GMT -5
Just think if instead of VDEX MannKind made a deal with Walgreens healthcare clinic's or CVS Minute Clinics and targeted both T1D and TD2 patients Tied into the One Drop Technology. Think about how many opportunities the company would have to sell the product. While VDEX has not been the success any of us said hope for perhaps MannKind should try to do a test market with either Walgreens or CVS.
|
|
|
Post by kc on May 27, 2017 7:36:46 GMT -5
My 92-year-old father had a spirometer test last week. I sat and watched it. It was in a pulmonologist doctors office. It took all of about five minutes. Handheld device. Had Bluetooth connection to her laptop. So this spirometer should not be an issue for anybody it was such a simple fast test
|
|
|
Post by kc on May 27, 2017 7:34:18 GMT -5
Learned last night that a friend of a friend died last week from an allergic reaction while in possession of her Epipen. I don't know the details of why she did not use it. Is this common? Horrible sorry to hear about your friend's passing
|
|
|
Post by kc on May 24, 2017 21:59:12 GMT -5
It sounds like it's going to be a great presentation by the mannkind presenter.
Case Study: Selecting Sensors to Improve Device Performance Speaker: John Pocreva, Senior Engineer, MannKind Corporation Sensor technology is moving rapidly in healthcare, and it's important for device developers to choose sensors that improve the function of their devices. This case study will look at how MannKind Corporation used sensors to advance their device.
|
|
|
Post by kc on May 24, 2017 21:56:13 GMT -5
He posted a picture. But I don't think it's possible to copy it and post it on here. I'll try and Google him on ST. Some one is loading up! I sure hope to hell somebody is loading up and that the damn is going to break shortly.
|
|
|
Post by kc on May 24, 2017 18:16:26 GMT -5
Basically I received cards on the Friday before anybody else had received them and then by Monday I received for more. A total of eight cards. I called six different times to speak to the names on the cards. Left voicemail messages on those six times. Never once did I even get a call back. In my view AGEIS is a scam.
I did receive by email on Monday this week a response from MannKind. I have no issue with the response and understand why they did not respond to me prior to the shareholders meeting.
It basically was an apology saying that they were just trying to utilize the firm for messaging and they probably did not do it the right way. I have no animus towards the company in regards to the response.
|
|
|
Post by kc on May 24, 2017 18:08:45 GMT -5
Right on! On all accounts! Matt will carry out Al's plan with integrity. And Mike is so good at finding the key players to bring it all together:-) I had heard rumors that SNY was going to buy MNKD. I was told Al's asking price was too high and that shitty prove it deal was put in place. They should've sold 10 or 15% of the shares to Sanofi so they had skin in the game like Sanofi had with Regeneron. Hindsight is 2020 we have to look forward now rather than backwards.
|
|